New gene mutation linked to cancer drugs’ success
LONDON (Reuters) - Scientists have uncovered a second gene mutation that determines which patients will respond to the bowel cancer drugs Erbitux and Vectibix, opening the way to still more targeted treatment.
Treating patients based on their genetic make-up is a growing trend in oncology, and the latest research, reported at a medical meeting in Geneva on Thursday, suggests multiple mutations have a role to play.
Experts already knew that Erbitux, developed by ImClone and sold by Bristol-Myers Squibb and Merck KGaA, and Vectibix, from Amgen, only work in tumors containing the normal, or wild-type, version of a gene known as KRAS.
Now a second gene, called BRAF, has also been shown to be involved, though to a lesser extent.
KRAS mutations explain about 30-40 percent of cases in which patients fail to respond to Erbitux and Vectibix. But results of a study presented by Federica Di Nicolantonio of the University of Turin School of Medicine in Italy suggest that BRAF mutations may account for another 12 percent.
The research was presented at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Geneva.
Experts have argued about the market impact of using genetic markers as way to pre-select patients for treatment with costly modern cancer drugs.
Drug companies have welcomed the development, arguing it is good for long-term sales, but some analysts say sales are likely to take at least a short-term hit.
(Reporting by Ben Hirschler, editing by Will Waterman)
--------------------------------------------------------------------------------------------Related Posts:
FRANKFURT (Reuters) - Merck KGaA said on Wednesday a Phase II trial provided further evidence that its cancer drug Erbitux was particularly effective at fighting bowel tumors whose cells did not undergo a certain type of genetic mutation. The German drugs and chemicals maker said that 53 percent of patients who did not have a mutation
Full Post: Merck says study confirms efficacy of Erbitux drug
--------------------------------------------------------------------------------------------
By Susan Heavey WASHINGTON (Reuters) - U.S. health regulators are questioning whether clinical trials proposed by ImClone Systems and Amgen Inc will be adequate to show that patients with a certain type of gene are more likely to be helped by two cancer drugs, according to documents released on Friday. Early research has indicated that patients with
Full Post: FDA questions Lilly, Amgen cancer drug trials
--------------------------------------------------------------------------------------------
HONG KONG (Reuters) - Researchers in China and the United States have identified mutations of two genes which appear to make ethnic Chinese more susceptible to lung cancer, they wrote in the journal Cancer. Their finding involves two genes, ABCB1 and ABCC1, which were previously thought to be linked to eliminating carcinogens from the lungs and
Full Post: Experts identify gene variants linked to lung cancer
--------------------------------------------------------------------------------------------
By Julie Steenhuysen CHICAGO (Reuters) - A single gene appears to play a crucial role in deadly breast cancers, increasing the chances the cancer will spread and making it resistant to chemotherapy, U.S. researchers said on Monday. They found people with aggressive breast cancers have abnormal genetic alterations in a gene called MTDH, and drugs that block
Full Post: Scientists find a gene that makes cancer spread
--------------------------------------------------------------------------------------------
By Ben Hirschler LONDON (Reuters) - Nearly one in five cancer drugs entering development now reach the market, a remarkably good success rate given the high level of failures in other disease areas, British researchers said on Friday . A study by Cancer Research UK, based on 974 cancer drugs starting initial Phase I clinical trials since
Full Post: Modern cancer drugs more likely to get to market